The anti-cholinesterase activity was evaluated of the ethyl acetate fraction of the methanol extract of Myristica fragrans Houtt (Myristicaceae) seeds and of compounds isolated from it by various chromatographic techniques. The chemical structures of the compounds were determined from spectroscopic analyses (NMR data). Thirteen compounds (1-13) were isolated and identified. Compound 8 {[(7S)-8-(4-hydroxy-3-methoxyphenyl)-7-hydroxypropyl]benzene-2,4-diol} showed the most effective activity with an IC 50 value of 35.1 M, followed by compounds 2 [(8R,8S)-7-(3,4-methylenedioxyphenyl)-8,8-dimethyl-7-(3,4-dihydroxyphenyl)-butane] and 11 (malabaricone C) with IC 50 values of 42.1 and 44.0 M, respectively. This is the first report of significant anticholinesterase properties of M. fragrans seeds. The findings demonstrate that M. fragrans could be used beneficially in the treatment of Alzheimer's disease.
Alzheimer's disease (AD) is a neurodegenerative disease and the most frequent and predominant cause of dementia in the elderly, provoking progressive cognitive decline, psychobehavioral disturbances, memory loss, the presence of senile plaques, neurofibrillary tangles, and a decrease in cholinergic transmission [1a, 1b] . Increasing age is a risk factor for development of AD [1c-1e], with sporadic AD typically diagnosed in patients aged >65 years. An estimated 5.4 million people aged >65 had AD in 2011, and its projected prevalence by 2030 is 7.7 million [1f] . Currently available AD treatments are "symptomatic," that is, they improve cognition, but do not affect the underlying pathology of the disease; therefore, they have no action on continuing neurodegeneration and disease progression. In recent years, these factors, combined with the increasing age of the population and economic impact of AD, have spurred research into treatments that may slow neurodegeneration and thereby modify the progression of AD. To demonstrate that a compound slows disease progression rather than providing a symptomatic, cognitive-enhancing effect, clinical trials should last for at least 18 months [1g] . Although the pathogenesis of AD is complicated and involves numerous pathways, two major hypotheses are currently under consideration regarding the molecular mechanism, the cholinergic hypothesis and the amyloid cascade hypothesis. The focus herein is upon inhibitors of select cholinesterases (ChEs) to alleviate cholinergic deficits and improve neurotransmission and β-site amyloid precursor protein (APP) cleaving enzyme (BACE1; aspartyl protease, β-secretase, and memapsin) inhibitors to preclude formation and accumulation of amyloid β peptide (Aβ). Pursuant to this, both could be established as viable therapeutic targets for AD [1b, 1h-1j]. One treatment strategy to enhance cholinergic function is the use of acetylcholinesterase (AChE, EC 3.1.1.7) inhibitors to increase the amount of acetylcholine present in the synapses between cholinergic neurons [1k] . AChE inhibitor such as tacrine, one of the most extensively studied AChE inhibitors, has been shown to significantly improve cognitive function in Alzheimer's disease [1l, 1m] . Another AChE inhibitor, berberine, has been reported to ameliorate spatial memory impairment by activating microglia and senile plaque clearance [1l] . It also inhibits acetylcholinesterase activity and plays an important role in metabolic syndrome (1m). In addition, Peng et al. showed that an anti-amnesic effect of berberine is related to an increase in peripheral and central cholinergic neuronal system activity (1n).
As part of our continuing studies to discover AChE inhibitors from natural sources, we found that the methanol extract of Myristica fragrans Houtt (Myristicaceae) had appreciable inhibitory activity. M. fragrans is an aromatic evergreen tree cultivated in South Africa, India, and other tropical countries. The seed and aril of the fruit of are commonly known as nutmeg and mace, respectively. Nutmeg was imported into Europe during the 12th century, and has long been used indigenously as a spice in many kinds of foods. Nutmeg is also prescribed for medicinal purposes in Asia to treat many diseases, such as rheumatism, muscle spasms, decreased appetite, and diarrhea [2a] . It shows anti-inflammatory [2b], cytotoxic [2c, 2d] , and antioxidant activities [2d, 2e]. However, no study has specifically investigated the constituents of nutmeg with regard to AChE activity. Study of the ethyl acetate (EtOAc) soluble fraction of the methanol extract of seeds of M. fragrans resulted in the isolation of thirteen compounds (1-13). This paper describes The MeOH extract of the seed of M. fragrans was partitioned into n-hexane-, EtOAc-, n-butanol, and water-soluble fractions. In a preliminary experiment, the inhibitory effect of these fractions was tested at a concentration of 50 g/mL for AChE inhibitory activity. The results showed that the EtOAc fraction (82.4% inhibition) was approximately 2.5-fold more potent than the n-hexane fraction (28.2% inhibition), while the water fraction showed weak inhibitory activity. The EtOAc fraction was selected for further isolation of active components. Chromatographic purification of this fraction led to the isolation of thirteen compounds (1-13).
The structures of these compounds were determined as (8R,8S)-7- Compounds 1-13 were evaluated for their AChE inhibition activity using Ellman's method, with slight modification [3a] . As shown in Table 1 , compound 3 exhibited no inhibitory activity. Compound 8 showed the most effective activity with an IC 50 value of 35.1 M, whereas the other compounds exhibited only weak activity, with IC 50 values ranging from 42.1 to 88.1 M; berberine was used as a positive control (IC 50 value 0.1 M) [3b].
AChE is known as a substrate-specific enzyme, which degrades the neurotransmitter acetylcholine in nerve synapses. According to the cholinergic hypothesis, cholinesterase inhibitors enhance the signal transmission in nerve synapses by prolonging the effect of acetylcholine. The major biological role of the enzyme is the termination of impulse transmission by rapid hydrolysis of the cationic neurotransmitter acetylcholine [4a] . According to the cholinergic hypothesis, the memory impairment in patients with senile dementia from AD results in a deficiency in cholinergic function in the brain [4b]. Hence the most promising therapeutic strategy for activating central cholinergic functions has been the use of cholinomimetic agents. The aim of AChE inhibitors is to boost the endogenous level of acetylcholine in the brains of AD patients, and thereby boost cholinergic neurotransmission. AChE inhibitors, including tacrine and donepezil, have been prescribed for the treatment of AD. Although these AChE inhibitors have some benefits, additional therapeutics are urgently needed. Previously, natural plant components with lignan skeletons from other plants have also shown inhibitory effects on AChE activity. Megislignan . Behavioral studies suggested that gomisin A improves the long-term memory in amnestic mouse models induced by scopolamine treatment. The mechanism of action is its inhibitory activity on AChE in mouse brain homogenates [4f] . As in this study, some isolated lignans from M. fragrans can manifest AChE inhibitory activity. Such compounds have been purified from natural medicinal plants and from spices for many years all over the world. In addition to other medicinal properties, such as anti-inflammatory, anti-cancer, and antioxidant activities, the anti-cholinesterase activity is worthy of notice, because low-molecular weight materials can easily reach the site of action following oral administration, since they cross the bloodbrain barrier [4g] .
In this work, we demonstrated for the first time the AChE inhibitory activities of lignans from M. fragrans. A bioassay-guided fractionation study further revealed that the seeds contained phenolic compounds. Among them, compounds 1 and 7-9 were isolated from this plant for the first time. Our results also indicate that M. fragrans extract and its lignans may be useful in the treatment of AD. Further studies are required to demonstrate the in vivo activity of these isolated compounds. 
Extraction and isolation:
The seeds of M. fragrans (2 kg) were extracted 3 times (3 h  3 L) with refluxing methanol. After the solvent was removed under reduced pressure, the residue was suspended in H 2 O and then partitioned with n-hexane, EtOAc, and n-butanol, successively. The EtOAc soluble fraction (54 g) was chromatographic on a silica gel column (10  60 cm; 63-200 m particle size, Merck) using a stepwise gradient of CHCl 3 : MeOH (50:1 to 0:1, each 2 L) to yield 9 fractions (Fr.1-9), according to their TLC profiles. Fraction 4 (1.2 g) was subjected to reversed phase (ODS-A) CC (6.0 × 60 cm; 150 μm particle size) and eluted with MeOH: H 2 O (from 4:1 to 1:0, 3 L for each step) to afford 4 sub-fractions (Fr.4-1-Fr.4-4). Further purification of Fr.4-2 (350 mg) by semi-preparative Waters HPLC systems [using an isocratic solvent system of 75% MeOH in H 2 O + 0.1% trifluoroacetic acid (flow rate 5 mL/min) over 90 min; UV detection at 210 nm; YMC Pak ODS-A column (20 × 250 mm, 5 m particle size)] resulted in the isolation of compound 4 (44 mg; t R = 42.5 min). Compounds 1 (14.5 mg; t R = 44.8 min), 2 (14.5 mg, t R = 39.2 min), and 3 (23.3 mg, t R = 49.2 min) were isolated from Fr.7-3 (610 mg) by semipreparative Waters HPLC systems [using an isocratic solvent system of 70% MeOH in H 2 O + 0.1% trifluoroacetic acid (flow rate 5 mL/min) over 90 min; UV detection at 210 nm; YMC Pak ODS-A column (20 × 250 mm, 5 m particle size)]. Sub-fraction F.7-4 (359 mg) was also purified by semi-preparative HPLC [using an isocratic solvent system of 75% MeOH in H 2 O + 0.1% trifluoroacetic acid (flow rate 5 mL/min) over 90 min; UV detection at 210 nm; YMC Pak ODS-A column (20 × 250 mm, 5 m particle size)] resulted in the isolation of compounds 5 (19.5 mg, t R = 41.2 min) and 6 (21.2 mg, t R = 45.3 min). Further purification of Fr.5-3 (430 mg) by semipreparative Waters HPLC systems [using an isocratic solvent system of 70% MeOH in H 2 O + 0.1% trifluoroacetic acid (flow rate 5 mL/min) over 90 min; UV detection at 210 nm; YMC Pak ODS-A column (20 × 250 mm, 5 m particle size] resulted in the isolation of compounds 10 (14 mg; t R = 38.5 min), 12 (12 mg; t R = 44.8 min), and 13 (14 mg; t R = 48.2 min). Compounds 7 (5.7 mg, t R = 37.2 min), 8 (3.6 mg; t R = 40.8 min), and 11 (50.3 mg, t R = 44.2 min) were isolated from Fr.6-2 (410 mg) by semi-preparative Waters HPLC systems [using an isocratic solvent system of 65% MeOH in H 2 O + 0.1% trifluoroacetic acid (flow rate 5 mL/min) over 90 min; UV detection at 210 nm; YMC Pak ODS-A column (20 × 250 mm, 5 m particle size]. Sub-fraction F.6-3 (254 mg) was further purified by semi-preparative HPLC [using an isocratic solvent system of 75% MeOH in H 2 O + 0.1% trifluoroacetic acid (flow rate 5 mL/min) over 90 min; UV detection at 210 nm; YMC Pak ODS-A column (20 × 250 mm, 5 m particle size] resulted in the isolation of compound 9 (3.0 mg, t R = 46.2 min).
In vitro AChE enzyme assay: AChE inhibitory activities were measured using the spectrophotometric method developed by Ellman, with slight modification [3a, 4e] . ACh was used as the substrate. The reaction mixture contained: 140 L of sodium phosphate buffer (pH 8.0); 20 L of tested sample solution [final concentration (f.c.) 100 M for the compounds]; and 20 L of AChE solution (5 units/mL), which were mixed and incubated for 15 min at room temperature. All tested samples and the positive control (berberine) were dissolved in 10% analytical grade dimethyl sulfoxide (DMSO). The reaction was started with the addition of 10 L of dithiobisnitrobenzoic acid (DTNB, 0.01 M) and 10 L of acetylthiocholine iodide (AChI, 0.075 M). The hydrolysis of AChI was monitored by following the formation of the yellow 5-thio-2nitrobenzoate anion at 412 nm for 15 min, which resulted from the reaction of DTNB with thiocholine, released by the enzymatic hydrolysis of AChI. The reaction was performed in triplicate and recorded in 96-well microplates, using VERSA max (Molecular Devices, Sunnyvale, CA, U.S.A.). Percent inhibition was calculated from (1-S/E) x 100, where E and S were the respective enzyme activities without and with the tested sample, respectively. The AChE inhibitory activity of each sample was expressed in terms of the IC 50 value (M required to inhibit the hydrolysis of the substrate, ACh by 50%), as calculated from the log-dose inhibition curve.
Statistical analysis:
Values are expressed in mean ± SD. P value was calculated using one way ANOVA, followed by Dunnett's test for multiple comparisons. Values of p < 0.05 were considered significant in all cases.
